Call Us : 1.224.938.9523 meetings@worldeventsforum.com
The Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center and 1Florida ADRC present
  • 17th Annual Mild Cognitive Impairment Symposium
  • Special Topic Workshop
  • Alzheimer's Public Educational Forum

January 19-20, 2019 | Miami Beach, Florida, USA

2013 PowerPoint Presentations

(A full screen PPT link can be found under the embedded PPT displays)

Bennett MCI 0113 HO
MCI 2013 David Bennett – New Approaches to Understanding the Relationships of Risk Factors to Cognitive Decline

Sacuiu 2013
MCI 2013 Simona Sacuiu – The Flynn Effect; How Secular Changes Influence the Predictive Value of Cognitive Performance and the Role of Computer Tomography in Prodromal Dementia in the H70

Roberts, Rosebud MCI symposium 11-28-2012
MCI 2013 Rosebud Roberts – Rates and Predictors of Progression from Mild Cognitive Impairment to Dementia: The Mayo Clinic Study of Aging

RabinsMCIMeeting
MCI 2013 Peter Rabins – Risk Factors for Age of Onset of AD in the Cache County Study

Hendrie
MCI 2013 Hugh Hendrie – The Fluidity of MCI in the Community and the Role of Vascular Biomarkers in Predicting Progression in the Indianapolis-Ibadan Study

ganguli 2013
MCI 2013 Mary Ganguli – Risk Factors for MCI Development and for MCI Progression: Are They The Same?

dickerson_mcisymp_011913
MCI 2013 Brad Dickerson – The Cortical Signatures of Alzheimer’s Disease and Frontotemporal Degeneration: Quantitative MRI Biomarkers Detectable Prior to Dementia

VEMURI 2013
MCI 2013 Prashanthi Vemuri – Biomarkers, Cognitive Reserve and Cognition in Alzheimer’s Disease

Benzinger_Miami_Jan_2013_no_Avi
MCI 2013 Tammie Benzinger – Neuroimaging for Predicting and Measuring Progression in Preclinical Autosomal Dominant Alzheimer’s Disease

scheltens 2013
MCI 2013 Philip Scheltens – MRI, FDG-PET and EEG for Predicting Progression in Aging, MCI and AD

salloway MCI lecture 1-2013
MCI 2013 Steven Salloway – Highlights of Biomarker and Clinical Outcomes from Recent AD Treatment Trials

Morris MCI 2013
MCI 2013 John Morris – A New Era: DIAN and the Secondary Prevention of Symptomatic Alzheimer’s Disease

Sperling A4 - MCI Ranjan
MCI 2013 Reisa Sperling – Anti-Amyloid Treatment of Asymptomatic Alzheimer’s Disease: The A4 Study

FaganMCIforDistribution
MCI 2013 Anne Fagan – The Role of Fluid Biomarkers in Preclinical Alzheimer’s Treatment Trials

Golde - Solving the Dilemma of Treatment Versus Prevention Strategies 12 2012
MCI 2013 Todd Golde – Solving the Dilemma of Treatment Versus Prevention Strategies for Alzheimer’s Disease

Reiman 2013 Launching a new era MCI Symposium
MCI 2013 Eric Reiman – Launching the Era of Alzheimer’s Prevention Research

Karlawish_ ethical challenges of Preclinical AD prevention_submitted_18 dec
MCI 2013 Jason Karlawish – Addressing the Ethical Challenges of Preclinical AD Prevention Trials

Roberts, Scott MCI symposium talk Miami 2013 Final
MCI 2013 Scott Roberts – Consent for Revealing Biomarker Status in AD Prevention Trials

Landau 2013
Landau MCI 2013 Susan Landau – Measuring Progression in Alzheimer’s Disease Using Brain Imaging Tests